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Background: In a phase III trial in patients with castration-resistant prostate cancer (CRPC) and bone metastases,
denosumab was superior to zoledronic acid in reducing skeletal-related events (SREs; radiation to bone, pathologic
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fracture, surgery to bone, or spinal cord compression). This study reassessed the efﬁcacy of denosumab using symptom-
atic skeletal events (SSEs) as a prespeciﬁed exploratory end point.
Patients and methods: Patients with CRPC, no previous bisphosphonate exposure, and radiographic evidence of
bone metastasis were randomized to subcutaneous denosumab 120 mg plus i.v. placebo every 4 weeks (Q4W), or i.v.
zoledronic acid 4 mg plus subcutaneous placebo Q4W during the blinded treatment phase. SSEs were deﬁned as radi-
ation to bone, symptomatic pathologic fracture, surgery to bone, or symptomatic spinal cord compression. The relation-
ship between SSE or SRE and time to moderate/severe pain was assessed using the Brief Pain Inventory Short Form.
Results: Treatment with denosumab signiﬁcantly reduced the risk of developing ﬁrst SSE [HR, 0.78; 95% conﬁdence
interval (CI) 0.66–0.93; P = 0.005] and ﬁrst and subsequent SSEs (rate ratio, 0.78; 95% CI 0.65–0.92; P = 0.004) com-
pared with zoledronic acid. The treatment differences in the number of patients with SSEs or SREs were similar (n = 48
and n = 45, respectively). Among patients with no/mild pain at baseline, both SSEs and SREs were associated with mod-
erate/severe pain development (P < 0.0001). Fewer patients had skeletal complications, particularly fractures, when
deﬁned as SSE versus SRE.
Conclusion: In patients with CRPC and bone metastases, denosumab reduced the risk of skeletal complications
versus zoledronic acid regardless of whether the end point was deﬁned as SSE or SRE.
Key words: denosumab, zoledronic acid, symptomatic skeletal events, skeletal-related events, prostate cancer, phase III
introduction
Skeletal-related events (SREs) are an objective, clinically relevant
end point for the evaluation of disease-related complications in
patients with bone metastases [1]. In most clinical trials, SREs
have been deﬁned as radiation to bone, pathologic fracture,
surgery to bone, or spinal cord compression [2–4]. Among
patients with prostate cancer and bone metastases, SREs are
associated with a signiﬁcant decrease in patient function and
health-related quality of life [5]. The regulatory approval of
several bone-targeted agents, including pamidronate, zoledronic
acid, and denosumab, has been supported by their ability to
reduce SREs [6–10].
Denosumab is a fully human monoclonal antibody against
RANK ligand. In a phase III trial in patients with castration-
resistant prostate cancer, treatment with denosumab was asso-
ciated with a signiﬁcant delay in the time to ﬁrst on-study SRE
(deﬁned as radiation to bone, pathologic fracture assessed either
clinically or through routine radiographic scans, surgery to
bone, or spinal cord compression) compared with zoledronic
acid (median, 20.7 versus 17.1 months) [11]. In that trial, ﬁrst
on-study pathologic fractures accounted for ∼15% of ﬁrst SREs;
most pathologic fractures were identiﬁed by scheduled skeletal
surveys (at baseline and every 12 weeks on study) and did not
require the presence of symptoms.
Recent phase III trials in patients with metastatic prostate
cancer have used a new end point termed symptomatic skeletal
events (SSEs), deﬁned as radiation to bone, symptomatic patho-
logic fracture, surgery to bone, or symptomatic spinal cord
compression [12–14]. In contrast with SREs, ascertainment of
SSEs does not include scheduled radiographic assessments.
SSE-based primary end points will be used in a phase III trial
of radium-223 combined with abiraterone acetate in patients
with castration-resistant prostate cancer and bone metastases
(ClinicalTrials.gov, NCT02043678). The relationship between
SREs and SSEs as measures of skeletal complications is un-
deﬁned. The objective of this analysis was to assess SSEs as a
prespeciﬁed exploratory end point in the pivotal phase III trial
of denosumab versus zoledronic acid in patients with castration-
resistant prostate cancer and bone metastases.
patients andmethods
patients
This is an analysis of patients from a randomized, double-blind, phase III
trial (ClinicalTrials.gov, NCT00321620) [11]. Eligible patients were men
(aged 18 years) with histologically conﬁrmed prostate cancer, serum tes-
tosterone <50 ng/dl following chemical/surgical castration, prior hormonal
therapy, radiographic evidence of bone metastasis, Eastern Cooperative
Oncology Group (ECOG) performance status ≤2, and adequate renal and
hepatic function. Patients were excluded if they had any prior denosumab or
bisphosphonate treatment, investigational product exposure or participated
in another clinical trial within the previous 30 days; planned radiotherapy or
surgery to bone; brain metastasis; osteonecrosis or osteomyelitis of the jaw or
jaw condition requiring oral surgery; nonhealed or planned dental/oral
surgery; or life expectancy <6 months. Patients provided written informed
consent; the study protocol was approved by each site’s ethics committee.
study design and treatment
Patients were randomly assigned to receive either subcutaneous denosumab
120 mg plus i.v. placebo every 4 weeks or subcutaneous placebo plus i.v.
zoledronic acid 4 mg every 4 weeks. Zoledronic acid doses were adjusted for
renal function per the label using the Cockcroft-Gault formula and withheld
for signiﬁcant renal deterioration during the study. Denosumab doses were
not adjusted. Daily supplementation with calcium (500 mg) and vitamin
D (400 IU) was recommended unless hypercalcemia developed.
Randomization was stratiﬁed by previous SRE (yes versus no), prostate-spe-
ciﬁc antigen (PSA) level (<10 ng/ml versus 10 ng/ml), and current (within
6 weeks before randomization) chemotherapy for prostate cancer (yes versus
no).
statistical analysis
The primary end point of the phase III study was time to ﬁrst on-study SRE
(assessed as noninferiority), deﬁned as radiation therapy to bone (including
radioisotopes), pathologic fracture (excluding trauma), surgery to bone, or
spinal cord compression as previously reported [11]. Radiographic skeletal
surveys of the skull, spine, chest, pelvis, arm (from shoulder to elbow), and
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leg (from hip to knee) were performed within 4 weeks before randomization,
every 12 weeks thereafter, and at the end-of-study visit. Fractures and spinal
cord compression were conﬁrmed radiologically by a central reader. The
analyses were based on the data up to the primary analysis cutoff (when
∼745 patients experienced an on-study SRE).
In this analysis, SSEs as a preplanned exploratory end point were deﬁned
as a subset of SREs considered symptomatic by the investigators at the time
the event was ﬁrst noted. Events that became symptomatic at a later date
were not recorded in the database; therefore, they were not able to be
included in the analyses of SSE. SSEs were deﬁned as radiation to bone,
symptomatic pathologic fractures, surgery to bone, or symptomatic spinal
cord compression. Time to ﬁrst SSE, deﬁned as the time from randomization
to ﬁrst occurrence of SSE as noted by the investigators, was assessed using a
Cox proportional hazards model stratiﬁed by the randomization stratiﬁca-
tion factors, with treatment groups as the independent variable. Patients
without a known SSE were censored at the last date on study or at the
primary analysis cutoff date, whichever came ﬁrst. Time to a subsequent SSE
was deﬁned as the time from randomization to the subsequent SSE occurring
21 days after the previous SSE. The multiple event analysis (time to ﬁrst
and subsequent SSE) was assessed using an Andersen-Gill model stratiﬁed
by the randomization stratiﬁcation factors. There was no adjustment for
multiplicity in the analyses.
SSEs and SREs by type (radiation to bone, fracture, surgery to bone,
spinal cord compression) were also summarized. For ﬁrst skeletal events,
data for each type of SRE/SSE were assessed without considering when the
other event types occurred. For ﬁrst and subsequent events, if multiple event
types occurred on the same day, only one was selected because they were typ-
ically related (e.g. surgery to bone following symptomatic pathologic frac-
ture); the following hierarchical order was used: (i) spinal cord compression,
(ii) surgery to bone, (iii) fracture, and (iv) radiation to bone. For these
reasons, some ﬁrst and subsequent event types may not have been counted,
resulting in a lower incidence than for ﬁrst skeletal events (see Table 1). The
data for the ﬁrst SSE/SRE by type of ﬁrst SSE/SRE were also presented with
consideration of when the other event types occurred (see Table 2).
Among patients with no/mild pain at baseline, the association between
ﬁrst on-study SSE or SRE and time to moderate or severe pain (>4-point
worst pain score per the Brief Pain Inventory Short Form) [15] was assessed
using a Cox proportional hazards model with the ﬁrst on-study SSE or SRE
(as a time-dependent covariate), respectively, and with the baseline covari-
ates (including number of baseline bone metastases, baseline analgesic score,
baseline worst pain score, region, ethnic group/race), and stratiﬁed by treat-
ment and the randomized stratiﬁcation factors. Patients’ ﬁrst on-study SSE/
SRE was assessed beginning 28 days before the SSE/SRE occurrence.
results
patients
Overall, 951 patients randomized to zoledronic acid and 950
patients randomized to denosumab in the phase III study were
evaluable for efﬁcacy in the primary analysis. As reported previous-
ly [11], age, ECOG performance status, and the randomization
stratiﬁcation factors (baseline PSA 10 ng/ml, chemotherapy
≤6 weeks before randomization, and previous SRE) were balanced
between treatment arms.
incidence of symptomatic skeletal events
and skeletal-related events
In a comparison of SSE and SRE as end points, there were 296
fewer ﬁrst on-study SSEs than ﬁrst on-study SREs (641 versus
937, respectively), and there were 340 fewer ﬁrst and subsequent
on-study SSEs than ﬁrst and subsequent on-study SREs (738
versus 1078; Table 1). As anticipated, ﬁrst on-study pathologic
fractures were less numerous when deﬁned as SSE than when
deﬁned as SRE (36 versus 328), as were ﬁrst and subsequent on-
study fractures (32 versus 391). In addition, the numbers of ﬁrst
on-study surgery to bone, ﬁrst radiation to bone, and ﬁrst spinal
cord compression were similar when deﬁned as SSE or SRE.
symptomatic skeletal events and skeletal-related
events by treatment group
The numbers of patients with ﬁrst on-study SSE were fewer
in the denosumab arm (n = 241) versus the zoledronic acid arm
(n = 289; Table 2); similar results were observed for patients
with a ﬁrst on-study SRE. Among the patients with a conﬁrmed
ﬁrst on-study SSE, the numbers of patients in the denosumab
and zoledronic acid arms with each event type (radiation to
bone, symptomatic pathologic fracture, surgery to bone, and
symptomatic spinal cord compression) were similar except for
radiation to bone, which was less frequent in the denosumab
arm than in the zoledronic acid arm (203 versus 233); similar
results were observed for patients with a ﬁrst on-study SRE.
First and subsequent on-study SSEs occurred in fewer patients
in the denosumab arm (n = 329; 0.35 mean events per patient)
versus the zoledronic acid arm (n = 409; 0.43 mean events per
patient; Table 2); similar results were observed for patients with
ﬁrst and subsequent on-study SREs. Among the patients with
Table 1. Confirmed on-study skeletal events: comparison of SSEs
and SREs
Event SRE SSE Difference (n)
First skeletal event,a n 937 641 296
Spinal cord compressionb 82 78 4
Surgery to bone 24 24 0
Fracturec 328 36 292
Radiation to bone 503 503 0
First and subsequent skeletal event,c n 1078 738 340
Spinal cord compressionb 81 78 3
Surgery to bone 12 15 −3
Fractureb 391 32 359
Radiation to bone 594 613 −19
aData shown are the first of each SRE/SSE event type (radiation to
bone, fracture, or surgery to bone, or spinal cord compression)
without considering when the other event types first occurred.
bFor SSE, the incidence of symptomatic pathologic fractures and
symptomatic spinal cord compression is shown. For SRE, the incidence
of pathologic fractures and spinal cord compression is shown.
cFor first and subsequent skeletal events, regardless of whether
assessed as SRE or SSE, only events occurring 21 days after the
previous event were counted, and if multiple event types occurred on
the same day, only one event was counted based on the following
priority order (based on severity): (i) spinal cord compression, (ii)
surgery to bone, (iii) fracture, and (iv) radiation to bone. For these
reasons, some first and subsequent events may not have been counted,
resulting in a lower incidence than first skeletal events (e.g. 15 versus
24 surgery to bone events assessed as SSE).
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ﬁrst and subsequent on-study SSEs, the numbers of patients in
the zoledronic acid and denosumab arms with each event type
were similar except for radiation to bone, which was less fre-
quent in the denosumab arm than in the zoledronic acid arm
(272 versus 341); similar results were observed for patients with
ﬁrst and subsequent on-study SREs.
risk of symptomatic skeletal events
and skeletal-related events
Compared with zoledronic acid, denosumab reduced the risk of
ﬁrst on-study SSE by 22% [HR, 0.78; 95% conﬁdence interval
(CI) 0.66–0.93; P = 0.005; Figure 1A]. Similarly, denosumab
reduced the risk of ﬁrst and subsequent on-study SSE by 22%
versus zoledronic acid (rate ratio, 0.78; 95% CI 0.65–0.92;
P = 0.004; Figure 1B). The median time to ﬁrst on-study SSE
was not reached in the denosumab arm and was 24.2 months in
the zoledronic acid arm. As previously reported [11], denosu-
mab reduced the risk of ﬁrst on-study SRE, as well as the risk of
ﬁrst and subsequent SRE, by 18% versus zoledronic acid.
effect ofﬁrst skeletal-related event and
symptomatic skeletal event on time to moderate
or severe pain (>4-point worst pain score)
Among patients with no/mild pain at baseline, the risk of devel-
oping moderate to severe pain on study was increased for
patients with a ﬁrst on-study occurrence of either an SSE
(HR, 3.07; 95% CI 2.34–4.03; P < 0.0001) or an SRE (HR, 2.09;
95% CI 1.69–2.58; P < 0.0001; Figure 2).
discussion
In this analysis of a phase III trial in patients with castration-re-
sistant prostate cancer and bone metastases, treatment with
denosumab was associated with a reduced risk of skeletal com-
plications compared with zoledronic acid regardless of whether
the end point evaluated was SSE or SRE. The observed treatment
effect for denosumab was similar whether skeletal complications
were deﬁned as SSE (22% risk reduction) or SRE (18% risk re-
duction) [11]. Both SSEs and SREs were associated with an
onset of moderate or severe pain among patients with no/mild
pain at baseline.
Our observation that denosumab reduced the risk of skeletal
complications similarly whether deﬁned as SSE or SRE is con-
sistent with the results of other studies of bone-targeted
agents. In phase III studies of zoledronic acid in patients with
metastatic prostate cancer, the extent of the reduction in skel-
etal complications by zoledronic acid versus placebo appears to
be similar whether deﬁned as SSE (12% reduction) [14] or SRE
(9% reduction) [16].
SSEs include symptomatic pathologic fractures but not
asymptomatic, radiographically identiﬁed fractures, and it has
therefore been argued that SSEs may be a more clinically rele-
vant end point. However, evidence from an analysis of a multi-
center, randomized trial of zoledronic acid in patients with
prostate cancer and bone metastases suggested that any SRE (ra-
diation to bone, pathologic fracture, spinal cord compression,
surgery to bone, or change in antineoplastic therapy to treat
bone pain) ultimately has the potential to decrease patient-
reported quality of life [5]. In this population of patients with
Table 2. Confirmed on-study SSEs and SREs by treatment arm
Event Zoledronic acid (n = 951) Denosumab (n = 950) Difference (n)
First SSE,a n 289 241 48
Symptomatic spinal cord compression 38 26 12
Surgery to bone 5 3 2
Symptomatic pathologic fracture 13 9 4
Radiation to bone 233 203 30
First SRE,a n 386 341 45
Spinal cord compression 36 26 10
Surgery to bone 4 1 3
Pathologic fracture 143 137 6
Radiation to bone 203 177 26
First and subsequent SSEs, n 409 329 80
Symptomatic spinal cord compression 43 35 8
Surgery to bone 8 7 1
Symptomatic pathologic fracture 17 15 2
Radiation to bone 341 272 69
First and subsequent SREs, n 584 494 90
Spinal cord compression 44 37 7
Surgery to bone 7 5 2
Pathologic fracture 203 188 15
Radiation to bone 330 264 66
aData shown are for the first of any event type (radiation to bone, fracture, surgery to bone, or spinal cord compression) in the first SRE/SSE, with
consideration of when the other event types occurred.
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castration-resistant prostate cancer and bone metastases, we
have shown that both SSEs and SREs overall were associated
with an increased risk of moderate or severe pain among
patients with no/mild pain at baseline.
Several studies have shown evidence of beneﬁt from bone-tar-
geted therapy in patients with bone metastases [17]. In an ana-
lysis of phase III trials in patients with bone metastases from
solid tumors (other than breast or prostate cancer), treatment
with denosumab was associated with a reduced risk of SREs, as
well as delayed time to moderate or severe pain, worsened pain,
and increased pain interference versus zoledronic acid among
patients without pain at baseline [18]. Similarly, in a combined
analysis of three phase III trials in patients with bone metastases
from breast cancer, castration-resistant prostate cancer, or other
solid tumors, treatment with denosumab was associated with
delayed time to moderate or severe pain and pain interference
among patients without pain at baseline, and a reduced risk of
worsened health-related quality of life versus zoledronic acid
[15]. Treatment with denosumab was associated with delayed
time to increased pain interference, as well as greater cancer-
speciﬁc quality of life versus zoledronic acid [19]. The beneﬁt of
denosumab has also been demonstrated in patients previously
treated with a bisphosphonate [20, 21].
Our analyses of SSEs excluded asymptomatic fractures and
asymptomatic spinal cord compression identiﬁed by study-
speciﬁed scheduled radiographic assessments. The required
radiographic assessments, however, may have resulted in increa-
sed ascertainment of symptomatic events prompted by more
intense clinical evaluation following an abnormal imaging
study. Any study that requires scheduled radiographic assess-
ment shares this potential limitation of ascertainment bias for
determination of ‘symptomatic’ skeletal events. Alternatively,
because any skeletal event has the potential to become symp-
tomatic over time, this study may have underestimated the num-
ber of symptomatic fractures for some patients.
In summary, denosumab reduced the risk of skeletal compli-
cations compared with zoledronic acid in men with castration-
resistant prostate cancer and bone metastases regardless of
whether the end point was deﬁned as SSE or SRE. Both SREs
and SSEs were associated with development of moderate/severe
pain among patients with no/mild pain at baseline. These ana-
lyses provide further evidence for the superior ability of denosu-
mab to prevent skeletal complications versus zoledronic acid.
acknowledgement
The authors acknowledge Ben Scott (whose work was funded
by Amgen Inc.) and Lori (Gorton) Smette (Amgen Inc.) for as-
sistance in writing this manuscript.
funding
This work was supported by Amgen Inc.
disclosure
MRS has served as a consultant for Amgen Inc. REC has
received honoraria from Amgen Inc. and Bayer and has pro-
vided expert testimony for Novartis. LK has received honoraria
from Amgen Inc., GlaxoSmithKline, Sanoﬁ-Aventis, Ferring,
Janssen, Dendreon, Merck, and Profound; has participated in
advisory boards for Amgen Inc., Dendreon, Janssen, Ferring,
GlaxoSmithKline, and Profound; and has received research
funding from Bayer/Algeta, Ferring, Abbott, GlaxoSmithKline,
and EMD Serono. KP has served on advisory boards and as a
speaker for Amgen Inc. and Novartis. SN has served on advisory
boards for Amgen Inc., Sanoﬁ, Janssen, AstraZeneca, Astellas,
and Pﬁzer. KNC has served on advisory boards for Amgen Inc.
and Novartis. KF has served on advisory boards and as a
speaker for Amgen Inc. and Novartis. AB, RW, HW, and AB are
employees of and stockholders in Amgen Inc. PM declares no
conﬂict of interest.
references
1. Saylor PJ, Armstrong AJ, Fizazi K et al. New and emerging therapies for bone
metastases in genitourinary cancers. Eur Urol 2013; 63: 309–320.
2. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer:
an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578–583.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:
1588–1594.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal
morbidity. Clin Cancer Res 2006; 12: 6243s–6249s.
5. Weinfurt KP, Li Y, Castel LD et al. The signiﬁcance of skeletal-related events
for the health-related quality of life of patients with metastatic prostate cancer.
Ann Oncol 2005; 16: 579–584.
6. Aredia® (pamidronate disodium). Full Prescribing Information. East Hanover, NJ:
Novartis Pharmaceuticals Corp, 2012.
7. Zometa® (zoledronic acid). Full Prescribing Information. East Hanover, NJ: Novartis
Pharmaceutical Corp, 2014.
8. XGEVA® (denosumab). Full Prescribing Information. Thousand Oaks, CA: Amgen
Inc., 2013.
9. European Medicines Agency (EMA). Zometa® (zoledronic acid). Summary of
Product Characteristics. West Sussex, UK: Novartis Europharm Limited, 2014.
10. European Medicines Agency (EMA). XGEVA® (denosumab). Summary of Product
Characteristics. Breda, The Netherlands: Amgen Europe B.V., 2014.
11. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for
treatment of bone metastases in men with castration-resistant prostate cancer: a
randomised, double-blind study. Lancet 2011; 377: 813–822.
12. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in
metastatic prostate cancer. N Engl J Med 2013; 369: 213–223.
13. Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on
symptomatic skeletal events in patients with castration-resistant prostate cancer
and bone metastases: results from a phase 3, double-blind, randomised trial.
Lancet Oncol 2014; 15: 738–746.
14. James ND, Pirrie S, Brown JE et al. Clinical outcomes in patients with castrate-
refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial
TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA),
neither, or both (ISRCTN 12808747). J Clin Oncol 2013; 31: abstr LBA5000.
15. von Moos R, Body JJ, Egerdie B et al. Pain and health-related quality of life in
patients with advanced solid tumours and bone metastases: integrated results
from three randomized, double-blind studies of denosumab and zoledronic acid.
Support Care Cancer 2013; 21: 3497–3507.
16. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of
zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
J Natl Cancer Inst 2002; 94: 1458–1468.
17. Lipton A, Fizazi K, Stopeck AT et al. Superiority of denosumab to zoledronic acid
for prevention of skeletal-related events: a combined analysis of 3 pivotal,
randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082–3092.
18. Henry D, Vadhan-Raj S, Hirsh V et al. Delaying skeletal-related events in a
randomized phase 3 study of denosumab versus zoledronic acid in patients with
Volume 26 | No. 2 | February 2015 doi:10.1093/annonc/mdu519 | 
Annals of Oncology original articles
advanced cancer: an analysis of data from patients with solid tumors. Support
Care Cancer 2014; 22: 679–687.
19. Patrick D, Cleeland C, Fallowﬁeld L et al. Denosumab or zoledronic acid (ZA)
therapy on pain interference and cancer-speciﬁc quality of life (CSQoL) in patients
with castrate-resistant prostate cancer (CRPC) and bone metastases (BM). J Clin
Oncol 2014; 32: abstr 12.
20. Body JJ, Lipton A, Gralow J et al. Effects of denosumab in patients with bone
metastases with and without previous bisphosphonate exposure. J Bone Miner
Res 2010; 25: 440–446.
21. Fizazi K, Bosserman L, Gao G et al. Denosumab treatment of prostate cancer with
bone metastases and increased urine N-telopeptide levels after therapy with
intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009;
182: 509–515; discussion 515–506.
Annals of Oncology 26: 374–377, 2015
doi:10.1093/annonc/mdu518
Published online 12 November 2014
Long-term outcome of patients with clinical stage I
high-risk nonseminomatous germ-cell tumors 15 years
after one adjuvant cycle of bleomycin, etoposide,
and cisplatin chemotherapy
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Background: To report the long-term results of adjuvant treatment with one cycle of modiﬁed bleomycin, etoposide, and
cisplatin (BEP) in patients with clinical stage I (CS I) nonseminomatous germ-cell tumors (NSGCT) at high risk of relapse.
Patients and methods: In a single-arm, phase II clinical trial, 40 patients with CS I NSGCT with vascular invasion and/
or >50% embryonal cell carcinoma in the orchiectomy specimen received one cycle of adjuvant BEP (20 mg/m2 bleo-
mycin as a continuous infusion over 24 h, 120 mg/m2 etoposide and 40 mg/m2 cisplatin each on days 1–3). Primary end
point was the relapse rate.
Results: Median follow-up was 186 months. One patient (2.5%) had a pulmonary relapse 13 months after one BEP and
died after three additional cycles of BEP chemotherapy. Three patients (7.5%) presented with a contralateral metachro-
nous testicular tumor, and three (7.5%) developed a secondary malignancy. Three patients (7.5%) reported intermittent
tinnitus and one had grade 2 peripheral polyneuropathy (2.5%).
Conclusions: Adjuvant chemotherapy with one cycle of modiﬁed-BEP is a feasible and safe treatment of patients with
CS I NSGCT at high risk of relapse. In these patients, it appears to be an alternative to two cycles of BEP and to have a
lower relapse rate than retroperitoneal lymph node dissection. If conﬁrmed by other centers, 1 cycle of adjuvant BEP
chemotherapy should become a ﬁrst-line treatment option for this group of patients.
Key words: testicular cancer, chemotherapy, adjuvant therapy, high-risk
introduction
Patients with clinical stage I (CS I) nonseminomatous germ-cell
tumors (NSGCT) with vascular invasion (VI) have a 46%–50%
risk of relapse [1]. Positive retroperitoneal lymph nodes are
present in 20%–58% of cases, particularly when >50% embryon-
al cell carcinoma (EC) components are found in the orchiect-
omy specimen. Lymph node metastases are also seen in most
patients with pure EC plus VI [2]; hence, VI and EC >50% are
risk factors for relapse [3].
Treatment of CS I NSGCT remains controversial. Various
guidelines recommend a risk-adapted approach: active surveil-
lance with deferred treatment upon relapse, or adjuvant chemo-
therapy, or retroperitoneal lymph node dissection (RPLND),
followed by chemotherapy if necessary [4, 5]. All three modal-
ities achieve equivalent cure rates of 98%–99% [6].
Patients under active surveillance have recurrence rates
between 25% and 50% depending on their risk factors [1]. To
achieve a cure rate of 95%–100% with salvage chemotherapy [6],
three to four cycles of bleomycin, etoposide, and cisplatin (BEP)
are required.
RPLND is the only procedure to detect and remove lymph
node micrometastases. Its main drawbacks are an up to 29% risk
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